These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 33654317)
1. Increased mortality after intravitreal injections of anti-VEGF for neovascular AMD among patients with prior stroke or acute myocardial infarction. Chen YY; Lai YJ; Yen YF; Chou P Eye (Lond); 2022 Jan; 36(1):153-159. PubMed ID: 33654317 [TBL] [Abstract][Full Text] [Related]
2. Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration. Dalvin LA; Starr MR; AbouChehade JE; Damento GM; Garcia M; Shah SM; Hodge DO; Meissner I; Bakri SJ; Iezzi R JAMA Ophthalmol; 2019 May; 137(5):483-490. PubMed ID: 30703203 [TBL] [Abstract][Full Text] [Related]
3. Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. Hanhart J; Comaneshter DS; Freier-Dror Y; Vinker S Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):651-663. PubMed ID: 29429131 [TBL] [Abstract][Full Text] [Related]
4. The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol. Sevik MO; Aykut A; Özkan G; Dericioğlu V; Şahin Ö Int Ophthalmol; 2021 Sep; 41(9):2951-2961. PubMed ID: 33864577 [TBL] [Abstract][Full Text] [Related]
5. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data. Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480 [TBL] [Abstract][Full Text] [Related]
6. Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Obeid A; Gao X; Ali FS; Aderman CM; Shahlaee A; Adam MK; Kasi SK; Hyman L; Ho AC; Hsu J JAMA Ophthalmol; 2018 Nov; 136(11):1251-1259. PubMed ID: 30352121 [TBL] [Abstract][Full Text] [Related]
7. Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy. Chen YY; Chou P; Huang YF; Chien HJ; Wu YC; Lee CC; Huang LY; Chen HH BMC Ophthalmol; 2019 Dec; 19(1):268. PubMed ID: 31888553 [TBL] [Abstract][Full Text] [Related]
8. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278 [TBL] [Abstract][Full Text] [Related]
9. Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration. Szegedi S; Ebner C; Miháltz K; Wachter T; Vécsei-Marlovits PV BMC Ophthalmol; 2022 May; 22(1):228. PubMed ID: 35596203 [TBL] [Abstract][Full Text] [Related]
10. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study. Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561 [TBL] [Abstract][Full Text] [Related]
11. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration. Fauser S; Viebahn U; Muether PS Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605 [TBL] [Abstract][Full Text] [Related]
12. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Park DH; Sun HJ; Lee SJ Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933 [TBL] [Abstract][Full Text] [Related]
13. Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration. Seong HJ; Park YM; Kim J; Son KJ; Chung EJ Korean J Ophthalmol; 2022 Oct; 36(5):435-442. PubMed ID: 35989065 [TBL] [Abstract][Full Text] [Related]
14. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477 [TBL] [Abstract][Full Text] [Related]
15. Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients. Rahman W; Chen FK; Yeoh J; da Cruz L Graefes Arch Clin Exp Ophthalmol; 2013 Jun; 251(6):1483-8. PubMed ID: 23160538 [TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. Finger RP; Daien V; Eldem BM; Talks JS; Korobelnik JF; Mitchell P; Sakamoto T; Wong TY; Pantiri K; Carrasco J BMC Ophthalmol; 2020 Jul; 20(1):294. PubMed ID: 32680477 [TBL] [Abstract][Full Text] [Related]